Bluejay Diagnostics announces SYMON-II sepsis study enrollment completion
BJDX•SYMON-II study reaches enrollment target
Bluejay Diagnostics posted a press release on SYMON-II, confirming completion of enrollment in its multicenter clinical validation study.
The target of 750 sepsis patients was met ahead of schedule. The study evaluates the Symphony IL-6 test for 28-day all-cause mortality risk.
Preliminary enrolled-population data indicate about a 17% 28-day mortality rate. Results are expected after data cleaning and analysis.
